Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

FDA Approves Durvalumab for Bladder Cancer

May 1st 2017

The FDA has granted an accelerated approval to the PD-L1 inhibitor durvalumab (Imfinzi) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Dr. Drake Discusses Immunotherapy Agents in Bladder Cancer

April 28th 2017

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses immunotherapy agents in bladder cancer.

Dr. Choueiri on Existing Therapies for Kidney Cancer

April 26th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the current therapies for patients with kidney cancer.

Dr. McDermott on Immunotherapy-Related AEs in RCC

April 24th 2017

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

Combination Therapies for Advanced Bladder Cancer

April 22nd 2017

Highlights of Durvalumab for Advanced Bladder Cancer

April 22nd 2017

Use of Immune Checkpoint Inhibitors for Bladder Cancer

April 22nd 2017

Future Treatment Options for Advanced Bladder Cancer

April 22nd 2017

Durvalumab for Treatment of Advanced Bladder Cancer

April 22nd 2017

Immune Checkpoint Inhibitors for Advanced Bladder Cancer

April 22nd 2017

Promising Treatment Options for Advanced Bladder Cancer

April 22nd 2017

FDA Approval of Durvalumab for Advanced Bladder Cancer

April 22nd 2017

Treatment of Bladder Cancer-Immune Checkpoint Inhibitors

April 22nd 2017

FDA Approval of Durvalumab for Bladder Cancer

April 22nd 2017

Frontline Atezolizumab for Advanced Bladder Cancer

April 22nd 2017

Historic Perspective on Bladder Cancer Treatment

April 22nd 2017

Durvalumab FDA Approval for Bladder Cancer

April 22nd 2017

Bladder Cancer: Paradigm Changing Advances in Treatment

April 22nd 2017

Revolutionary Advances for Treating Urothelial Carcinoma

April 22nd 2017

FDA Approves Frontline Atezolizumab for Some Bladder Cancer Patients

April 18th 2017

The FDA has granted an accelerated approval to atezolizumab as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.